Glenmark Therapeutics has developed Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compared to the active ingredient in MiraLAX® Powder for Solution, 17 grams of Bayer HealthCare LLC.

According to Nielsen® syndicated data for the latest 52-week period ending February 22, 2025, the MiraLAX® Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately USD 555.7 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this.